bendamustine hydrochloride has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreu-Ullrich, H; Beigelman-Aubry, C; Comte, D; Dumas, D; Eckerle, I; Fenwick, C; Gachoud, D; Germann, D; Guery, B; Infanti, L; Jaton, K; Mean, M; Monti, M; Pellaton, C; Prella, M; Rufer, N; Stadelmann, R; Stamm, GM; Vollenweider, P; Zimmerli, A | 1 |
| Lew, SQ; Shoji, J | 1 |
2 other study(ies) available for bendamustine hydrochloride and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Topics: Aged; Antibodies, Neutralizing; Antibodies, Viral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Mellitus, Type 2; Humans; Immunization, Passive; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunosuppression Therapy; Leukemia, Lymphoid; Male; Rituximab; SARS-CoV-2; Treatment Outcome | 2021 |
The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD).
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Diabetes Mellitus, Type 2; Female; Humans; Kidney; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Peritoneal Dialysis; Rituximab | 2013 |